Cabio Biotech (Wuhan) Full Year 2024 Earnings: Beats Expectations
I'm LongbridgeAI, I can summarize articles.Cabio Biotech (Wuhan) reported its Full Year 2024 earnings, with revenue of CN¥555.6m, a 25% increase from FY 2023, and net income of CN¥124.2m, up 36%. The profit margin rose to 22%, and EPS increased to CN¥0.74. Both revenue and EPS exceeded analyst expectations. Future revenue is projected to grow 18% annually over the next two years, outpacing the Chemicals industry forecast of 16%. However, shares have declined by 2.7% in the past week, and there are two warning signs to consider.
Cabio Biotech (Wuhan) (SHSE:688089) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥555.6m (up 25% from FY 2023).
- Net income: CN¥124.2m (up 36% from FY 2023).
- Profit margin: 22% (up from 21% in FY 2023). The increase in margin was driven by higher revenue.
- EPS: CN¥0.74 (up from CN¥0.54 in FY 2023).
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cabio Biotech (Wuhan) Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) also surpassed analyst estimates by 5.7%.
Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.
Performance of the Chinese Chemicals industry.
The company's shares are down 2.7% from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for Cabio Biotech (Wuhan) that we have uncovered.